Free tool
FAERS Monitor: Metadate Cd
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021259 or its brand name (Metadate Cd, Methylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,354
Serious
4,534
62% of reports
Hospitalization
1,756
Death reported
445
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,098
- headache417
- fatigue370
- anxiety363
- off label use347
- nausea346
- toxicity to various agents334
- product substitution issue299
- drug abuse286
- insomnia283
- somnolence282
- disturbance in attention245
- suicidal ideation245
- decreased appetite235
- agitation227
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 18 |
| 2006 | 18 |
| 2007 | 25 |
| 2008 | 26 |
| 2009 | 30 |
| 2010 | 28 |
| 2011 | 32 |
| 2012 | 90 |
| 2013 | 120 |
| 2014 | 127 |
| 2015 | 465 |
| 2016 | 401 |
| 2017 | 512 |
| 2018 | 591 |
| 2019 | 473 |
| 2020 | 370 |
| 2021 | 412 |
| 2022 | 619 |
| 2023 | 794 |
| 2024 | 752 |
| 2025 | 746 |
| 2026 | 683 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,805 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product substitution issueSignal | 299 | 14.9 | 13.4 | 3,861 |
| disturbance in attentionSignal | 245 | 13.0 | 11.5 | 2,708 |
| drug abuseSignal | 286 | 9.9 | 8.8 | 2,268 |
| agitationSignal | 227 | 8.9 | 7.8 | 1,577 |
| suicidal ideationSignal | 245 | 7.7 | 6.8 | 1,417 |
| toxicity to various agentsSignal | 334 | 5.7 | 5.1 | 1,289 |
| somnolenceSignal | 282 | 4.0 | 3.6 | 639 |
| anxietySignal | 363 | 3.7 | 3.3 | 705 |
| insomniaSignal | 283 | 3.0 | 2.7 | 390 |
| decreased appetiteSignal | 235 | 2.9 | 2.6 | 293 |
| drug ineffectiveSignal | 1,098 | 2.4 | 2.3 | 939 |
| headache | 417 | 1.9 | 1.7 | 183 |
| fatigue | 370 | 1.4 | 1.2 | 36 |
| nausea | 346 | 1.3 | 1.1 | 18 |
| off label use | 347 | 1.1 | 1.0 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.